Share ownership Mesoblast Limited

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 05:10:27 16/01/2026 GMT			5-day change	1st Jan Change
2.640 ^AUD	-2.22%		-10.51%	-2.94%

02:24am	ASX Biggest Losers	MT
01-14	ASX Biggest Losers	MT

Share class: Mesoblast Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,141,784,114	850,272,705 ( 74.47 %)	542,903 ( 0.0475 %)	74.47 %

Major shareholders: Mesoblast Limited

Name	Equities	%	Valuation
Gregory George 20.87 %	267,815,622	20.87 %	486 M $
Silviu Itescu 6.154 %	78,958,928	6.154 %	143 M $
William Gueck 5.002 %	64,171,900	5.002 %	116 M $
Thorney Investment Group Australia Pty Ltd. 1.1 %	14,116,398	1.1 %	26 M $
Josaka Investments Pty Ltd. 0.6876 %	8,821,137	0.6876 %	16 M $
BetaShares Capital Ltd. 0.5654 %	7,254,288	0.5654 %	13 M $
Eric Rose 0.5261 %	6,749,274	0.5261 %	12 M $
State Street Global Advisors Trust Co. 0.4847 %	6,218,488	0.4847 %	11 M $
Kenneth Martin Keane 0.2084 %	2,674,024	0.2084 %	5 M $
Independent Asset Management Pty Ltd. 0.1657 %	2,125,865	0.1657 %	4 M $
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Legal & General Investment Management Ltd. 0.5077 %	651,416	0.5077 %	12 M $
Aperio Group LLC 0.4002 %	513,399	0.4002 %	9 M $
Morgan Stanley Capital Services LLC 0.3631 %	465,801	0.3631 %	8 M $
Goldman Sachs & Co. LLC 0.3175 %	407,280	0.3175 %	7 M $
Susquehanna Securities LLC 0.2116 %	271,488	0.2116 %	5 M $
Summit X LLC 0.1553 %	199,295	0.1553 %	4 M $
UBS Financial Services, Inc. 0.1216 %	156,025	0.1216 %	3 M $
Bank of America NA (Charlotte, North Carolina) 0.0869 %	111,459	0.0869 %	2 M $
RBC Dominion Securities, Inc. 0.0713 %	91,461	0.0713 %	2 M $
Penbrook Management LLC 0.0683 %	87,575	0.0683 %	2 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	32.9%
Institutional	2.89%
Other	0.76%
Unknown	63.45%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	32.9%
Australia	2.68%
United States	0.82%
United Kingdom	0.08%
Ireland	0.05%
Canada	0.01%
New Zealand	0.01%

Based on 1000 largest holdings

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-25 - Q2 2026 Earnings Release (Projected)

More about the company